Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults | Zendy

Tara Lindeman | Zendy; Joan Duggan | Zendy; Eric G. Sahloff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults

Author(s) -

Tara Lindeman,

Joan Duggan,

Eric G. Sahloff

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw053

Subject(s) - creatinine , medicine , regimen , integrase inhibitor , renal function , adverse effect , integrase , human immunodeficiency virus (hiv) , virology , pharmacology , viral load , antiretroviral therapy

This retrospective chart review evaluated changes in serum creatinine and creatinine clearance (CrCl) after initiation of an integrase inhibitor (INSTI)-based regimen as initial treatment in human immunodeficiency virus-infected adults. Serum creatinine and CrCl changes were similar to those seen in clinical trials for INSTIs. No renal-related serious adverse events or discontinuations occurred.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research